http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0609427-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2006-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff9ab3d365f2236ced309ba95e18fdfa |
| publicationDate | 2010-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0609427-A2 |
| titleOfInvention | pharmaceutical composition for the treatment of prostate cancer and use of a hormone therapy agent and an antibody, or an antigen binding portion thereof |
| abstract | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PROSTATE CANCER AND THE USE OF A HORMONAL THERAPY AGENT AND ANTIBODY, OR AN ANTIGEN-BINDING PART OF THE SAME. The present invention relates to methods for treating prostate cancer comprising administering an anti-CTLA4 antibody, or an antigen binding portion thereof, particularly a human antibody to human CTLA4, for example antibody 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticiíimumab (also known as 11.2.1), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipiimumab (also known as MDX-010 and 10D1) along with hormone therapy. Hormone therapy agents include, inter alia, an antiandrogen (eg megestrol, cyproterone, flutamide, nilutamide and bicalutamide), a GnRH antagonist (eg abareix and histrelin) and an LH-RH agonist (e.g. leuprolide, goserelin and buserelin). The invention relates to neoadjuvant therapy, adjuvant therapy, PSA augmentation therapy, first-line therapy, second-line therapy, and third-line therapy for prostate cancer, whether localized or metastatic. |
| priorityDate | 2005-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 745.